Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma, Liver Metastasis
Conditions
Brief summary
The study enrolls patients with non-resectable or borderline resectable hepatocellular carcinoma (HCC), intraheaptic choalngiocarcinoma (IHCC) or colorectal cancer metastasis. Patients are not a candidates for liver transplantation and have only limited extrahepatic disease. All patients are treated with radioembolization. Primary endpoint is the percentage of patients that can be downstaged to resectability. Secondary endpoints are radiologic response to radioembolization,tissue response to radiomembolization and systemic immune response and intra-tumoral T-cell response to radioembolization. * Trial with radiotherapy
Interventions
RADIATIONInjection of Ytttrium-90 microspheres into the hepatic artery
INjection of Y-90 particles into the hepatic artery using endovascular access
Sponsors
University of Zurich
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
- Patients already considered for radioembolization fulfil criteria to be included in the study. If radioembolization is not considered by the tumor board, inclusion in the study should not be considered. \- Non-resectable or borderline resectable liver tumors (HCC, CRCM or CCC) as as-sessed by a multidisciplinary tumor-board. Non-resectability or borderline resectablily is based closeness to essential nonresectable structures (f.e. the portal vein bifurca- tion or hepatic vein trifurcation) or insufficient liver volume after resection, general performance status of the patient. Chemotherapy (mostly applicable to CRCM) should be termininated at least 4 weeks prior to enrolling patients in the study. * Concomitant manoevers to manipulate liver volume like portal vein embolization or ligation and two-stage resections are allowed * Male or female patients 18-99 years of age * Presentation of the case at the Multidisciplinary Meeting attended by hepatobiliary surgeons, oncologists, hepatologists and radiologists * Written informed consent given by the patient * Adequate liver function or kidney function tests, including any of the following. It is possible to perform endoscopic or percutaneous stent placement to achieve normal-isation of laboratory parameters. * Women who are not breastfeeding and are using effective contraception if sexually active, who are not pregnant and agree not to become pregnant during the 12 months thereaf-ter. A negative pregnancy test before inclusion into the trial is required for women \< 50 years. Men who agree not to father a child during participation in the trial or during the 12 months thereafter. * Effective contraception Patient compliance and geographic proximity
Exclusion criteria
-Patients with no clinical indications for radioembolization (resectable tumors, no need for downsizing) * contraindications on ethical grounds, * women who are pregnant or breast feeding, * significant concomitant disease states (e.g., renal failure, hepatic dysfunction, cardi-ovascular disease, etc) as based on above mentioned labaratory values or preopera-tive cardiac assessment making the patient unsuitable for major surgery known or suspected non-compliance, drug or alcohol abuse, enrolment into a clinical trial within last 4 weeks, extrahepatic tumor burden, as evaluated by PET/CT or chest CT. Potentially resectable small lung nodules or hilar lymphadenopathy by CT or PET in case of MCRC mandate systemic chemotherapy prior to enrolment into this trial if not already performed. The patient may be en-rolled into this trial to be downstaged by radioembolization after finishing systemic chemotherapy. * Anatomic variant in arteriogram which prevents selective delivery of the chemother-apy to the liver (discussed within group of principal investigators) * Life expectancy \< 3 months * Candidacy for liver transplantation in the case of HCC
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary endpoint ist the percentage of patients that can be downstaged to resectability | 2012 to 2015 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Histologic response to radioembolization | 2012 to 2015 | Resected specimen will be examined for changes related to radioembolization like endothelial damage, necrosis, fibrosis |
| Immunological response to radioembolization | 2012 to 2015 | Circulating T-cells and tissue based T-cells will be examined for their response to tumor antigens, clonal proliferation. Serologic response to tumor antigens will be examined |
Countries
Switzerland
Outcome results
None listed